Boussios S, Rassy E, Samartzis E, Moschetta M, Sheriff M, Pérez-Fidalgo JA, et al. Melanoma of unknown primary: new perspectives for an old story. Crit Rev Oncol Hematol. 2021;158: 103208. https://doi.org/10.1016/j.critrevonc.2020.103208.

Article  PubMed  Google Scholar 

Persa O-D, Hassel JC, Steeb T, Erdmann M, Karimi B, Stege H, et al. Brief communication: treatment outcomes for advanced melanoma of unknown primary compared with melanoma with known primary. J Immunother. 2024;47:384–7. https://doi.org/10.1097/CJI.0000000000000537.

Article  PubMed  Google Scholar 

Kreidieh FY, Tawbi HA. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition. Ther Adv Med Oncol. 2023;15:17588359231186028. https://doi.org/10.1177/17588359231186027.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, et al. Final 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. New Engl J Med. 2024. https://doi.org/10.1056/NEJMoa2407417.

Article  PubMed  Google Scholar 

Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Gutiérrez EC, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. New Engl J Med. 2022;386:24–34. https://doi.org/10.1056/NEJMoa2109970.

Article  CAS  PubMed  Google Scholar 

Lowe KL, Cole D, Kenefeck R, OKelly I, Lepore M, Jakobsen BK. Novel TCR-based biologics: mobilising T cells to warm ‘cold’ tumours. Cancer Treat Rev. 2019;77:35–43. https://doi.org/10.1016/j.ctrv.2019.06.001.

Article  CAS  PubMed  Google Scholar 

Hamid O, Sato T, Davar D, Callahan MK, Thistlethwaite F, Aljumaily R, et al. 728O Results from phase I dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors. Ann Oncol. 2022;33:S875. https://doi.org/10.1016/j.annonc.2022.07.854.

Article  Google Scholar 

Hassel JC, Piperno-Neumann S, Rutkowski P, Baurain J-F, Schlaak M, Butler MO, et al. Three-year overall survival with tebentafusp in metastatic uveal melanoma. New Engl J Med. 2023;389:2256–66. https://doi.org/10.1056/NEJMoa2304753.

Article  CAS  PubMed  Google Scholar 

Sunshine JC, Nguyen PL, Kaunitz GJ, Cottrell TR, Berry S, Esandrio J, et al. PD-L1 expression in melanoma: a quantitative immunohistochemical antibody comparison. Clin Cancer Res. 2017;23:4938–44. https://doi.org/10.1158/1078-0432.CCR-16-1821.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ellebaek E, Khan S, Bastholt L, Schmidt H, Haslund CA, Donia M, et al. PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma. Eur J Cancer. 2024;198: 113476. https://doi.org/10.1016/j.ejca.2023.113476.

Article  CAS  PubMed  Google Scholar 

Placke J-M, Kimmig M, Griewank K, Herbst R, Terheyden P, Utikal J, et al. Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma—analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM. EBioMedicine. 2023;96: 104774. https://doi.org/10.1016/j.ebiom.2023.104774.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14:847–56. https://doi.org/10.1158/1535-7163.MCT-14-0983.

Article  CAS  PubMed  Google Scholar 

Krishnamurthy N, Nishizaki D, Lippman SM, Miyashita H, Nesline MK, Pabla S, et al. High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome. Ther Adv Med Oncol. 2024;16:17588359231220510. https://doi.org/10.1177/17588359231220510.

Article  PubMed  PubMed Central  Google Scholar 

Gide TN, Paver EC, Yaseen Z, Maher N, Adegoke N, Menzies AM, et al. Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies. Oncoimmunology. 2023;12:2261248. https://doi.org/10.1080/2162402X.2023.2261248.

Article  PubMed  PubMed Central  Google Scholar 

Andrews LP, Butler SC, Cui J, Cillo AR, Cardello C, Liu C, et al. LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity. Cell. 2024;187:4355-4372.e22. https://doi.org/10.1016/j.cell.2024.07.016.

Article  CAS  PubMed  Google Scholar 

Revythis A, Shah S, Kutka M, Moschetta M, Ozturk MA, Pappas-Gogos G, et al. Unraveling the wide spectrum of melanoma biomarkers. Diagnostics. 2021;11:1341. https://doi.org/10.3390/diagnostics11081341.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ning B, Liu Y, Wang M, Li Y, Xu T, Wei Y. The predictive value of tumor mutation burden on clinical efficacy of immune checkpoint inhibitors in melanoma: a systematic review and meta-analysis. Front Pharmacol. 2022;13: 748674. https://doi.org/10.3389/fphar.2022.748674.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fumet J-D, Truntzer C, Yarchoan M, Ghiringhelli F. Tumour mutational burden as a biomarker for immunotherapy: current data and emerging concepts. Eur J Cancer. 2020;131:40–50. https://doi.org/10.1016/j.ejca.2020.02.038.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Andrews MC, Li G, Graf RP, Fisher VA, Mitchell J, Aboosaiedi A, et al. Predictive impact of tumor mutational burden on real-world outcomes of first-line immune checkpoint inhibition in metastatic melanoma. JCO Precis Oncol. 2024;2024: e2300640. https://doi.org/10.1200/PO.23.00640.

Article  Google Scholar 

Ascierto PA, Casula M, Bulgarelli J, Pisano M, Piccinini C, Piccin L, et al. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. Nat Commun. 2024;15:146. https://doi.org/10.1038/s41467-023-44475-6.

Article  PubMed  PubMed Central  Google Scholar 

Stonesifer CJ, Djavid AR, Grimes JM, Khaleel AE, Soliman YS, Maisel-Campbell A, et al. Immune checkpoint inhibition in non-melanoma skin cancer: a review of current evidence. Front Oncol. 2021. https://doi.org/10.3389/fonc.2021.734354.

Article  PubMed  PubMed Central  Google Scholar 

Turajlic S, Litchfield K, Xu H, Rosenthal R, McGranahan N, Reading JL, et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 2017;18:1009–21. https://doi.org/10.1016/S1470-2045(17)30516-8.

Article  CAS  PubMed  Google Scholar 

Rozeman EA, Menzies AM, van Akkooi ACJ, Adhikari C, Bierman C, van de Wiel BA, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 2019;20:948–60. https://doi.org/10.1016/S1470-2045(19)30151-2.

Article  CAS  PubMed  Google Scholar 

Whitman ED, Koshenkov VP, Gastman BR, Lewis D, Hsueh EC, Pak H, et al. Integrating 31-gene expression profiling with clinicopathologic features to optimize cutaneous melanoma sentinel lymph node metastasis prediction. JCO Precis Oncol. 2021;5:1466–79. https://doi.org/10.1200/PO.21.00162.

Article  Google Scholar 

Reschke R, Gussek P, Ziemer M. Identifying high-risk tumors within AJCC stage IB–III melanomas using a seven-marker immunohistochemical signature. Cancers (Basel). 2021;13:2902. https://doi.org/10.3390/cancers13122902.

Article  CAS  PubMed  Google Scholar 

Meyer S, Fuchs TJ, Bosserhoff AK, Hofstädter F, Pauer A, Roth V, et al. A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts. PLoS ONE. 2012;7: e38222. https://doi.org/10.1371/journal.pone.0038222.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hsueh EC, DeBloom JR, Lee JH, Sussman JJ, Covington KR, Caruso HG, et al. Long-term outcomes in a multicenter, prospective cohort evaluating the prognostic 31-gene expression profile for cutaneous melanoma. JCO Precis Oncol. 2021;5:589–601. https://doi.org/10.1200/PO.20.00119.

Article